Skip to main content



06-18-2018 | Dulaglutide | News

Dulaglutide feasible alternative to insulin glargine in patients with CKD

Once-weekly dulaglutide lowers glycated hemoglobin levels to a similar degree to titrated daily insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease, study findings indicate.

06-13-2018 | Nephropathy | News

Dapagliflozin of value in type 2 diabetes with moderate kidney impairment

Twenty-four weeks of treatment with dapagliflozin significantly improves glycemic control, body weight and systolic blood pressure in patients with type 2 diabetes and moderate kidney impairment, phase III study data show.

06-12-2018 | Metformin | News

Cautious metformin use supported with moderately reduced renal function

The risk for acidosis during metformin treatment is no higher than that during alternative treatment among patients with type 2 diabetes and an estimated glomerular filtration rate below 30 mL/min per 1.73 m2, study data show.

Read more

Related topics




11-04-2016 | Clinical trial | Editorial | Article

My EASD 2016 Highlights: From Paleolithic diets to the artificial pancreas

Editorial board member John Wilding outlines key moments from the 52nd annual meeting of the European Association for the Study of Diabetes in Munich, Germany.

Journal articles and book chapters

05-08-2018 | Type 2 diabetes | Review | Article

Type 2 diabetes in youth: New lessons from the SEARCH study

Jensen ET, Dabelea D. Curr Diab Rep 2018; 18: 36. doi: 10.1007/s11892-018-0997-1

04-28-2018 | Heart failure | Review | Article

SGLT2 inhibition and heart failure: Current concepts

Custodio JS et al. Heart Fail Rev 2018; 23: 409–418. doi: 10.1007/s10741-018-9703-2

04-16-2018 | Type 1 diabetes | Review | Article

The potential role of SGLT2 inhibitors in the treatment of type 1 diabetes mellitus

Fattah H, Vallon, V. Drugs 2018; 78: 717–726. doi: 10.1007/s40265-018-0901-y

Case reports

image credits